

1258032

UNITED STATES PATENT AND TRADEMARK OFFICE

"TO ALL TO WHOM IT CONCERNIS: BE IT KNOWN, CONCERNIS:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 08, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/520,908
FILING DATE: *November 17, 2003*
RELATED PCT APPLICATION NUMBER: PCT/US04/37789

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).


Express Mail Label No. EL 961008016 US

INVENTOR(S)		
Given Name (first and middle [if any]) Adam Laurence H.	Family Name or Surname SIDDQUI-JAIN HURLEY	Residence (City and either State or Foreign Country) San Diego, California Tucson, Arizona
Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max) METHODS FOR IDENTIFYING MODULATORS OF QUADRUPLEX NUCLEIC ACIDS		
Direct all correspondence to: CORRESPONDENCE ADDRESS		
<input checked="" type="checkbox"/> Customer Number:	25225	
OR		
<input type="checkbox"/> Firm or Individual Name		
Address		
City	State	Zip
Country	Telephone	Fax
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages	37	<input type="checkbox"/> CD(s), Number
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	3	<input checked="" type="checkbox"/> Other
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		Return Receipt Postcard (specify):
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 03-1952 referencing fees or credit any overpayment to Deposit Account Number: 532233001400	80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____	

[Page 1 of 1]

Respectfully submitted,

Date November 17, 2003

SIGNATURE
TYPED OR
PRINTED NAME

 Bruce D. Grant
REGISTRATION NO.
(if appropriate) 47,608

TELEPHONE

(858) 720-7962

Docket Number: 532233001400

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 961008016 US, in an envelope addressed to: MS Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/17/03

Signature:  (Judy Bridgwater)USPTO
601520918
111703

Application No. (if known):

Attorney Docket No.: 532233001400

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EL 961008016 US in an envelope addressed to:

MS Provisional Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 17, 2003
Date



Signature

Judy Bridgwater

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Application Data Sheet

**METHODS FOR IDENTIFYING MODULATORS OF
QUADRUPLEX NUCLEIC ACIDS**

Field of the Invention

[0001] The invention concerns methods for identifying molecules that modulate a biological activity of a nucleic acid capable of forming secondary structures such as G-quadruplexes.

Background

[0002] Developments in molecular biology have led to an understanding of how certain therapeutic compounds interact with molecular targets and lead to a modified physiological condition. Specificity of therapeutic compounds for their targets is derived in part from interactions between complementary structural elements in the target molecule and the therapeutic compound. A greater variety of target structural elements in the target leads to the possibility of unique and specific target/compound interactions. Because polypeptides are structurally diverse, researchers have focused on this class of targets for the design of specific therapeutic molecules.

[0003] In addition to therapeutic compounds that target polypeptides, researchers also have identified compounds that target DNA. Some of these compounds are effective anticancer agents and have led to significant increases in the survival of cancer patients. Unfortunately, however, these DNA targeting compounds do not act specifically on cancer cells and therefore are extremely toxic. Their unspecific action may be due to the fact that DNA often requires the uniformity of Watson-Crick duplex structures for compactly storing information within the human genome. This uniformity of DNA structure does not offer a structurally diverse population of DNA molecules that can be specifically targeted.

[0004] Nevertheless, there are some exceptions to this structural uniformity, as certain DNA sequences can form unique secondary structures. For example, intermittent runs of guanines can form G-quadruplex structures, and complementary runs of cytosines can form i-motif structures. Formation of G-quadruplex and i-motif structures occurs when a particular region of duplex DNA transitions from Watson-Crick base pairing to intermolecular and intramolecular single-stranded structures.

Summary

[0005] Certain regulatory regions in duplex DNA can transition into single-stranded G-quadruplex structures that regulate important biological processes. A gene in proximity to a G-quadruplex structure often is not appreciably transcribed into RNA, and certain proteins induce transcription and activation of the gene by facilitating the transition of quadruplex structures into transcribable structures. G-quadruplexes in intramolecular parallel (IP) conformations now have been identified as transcription regulators in certain nucleic acids. This discovery thereby allows for the design of candidate molecules capable of modulating the biological activity of nucleic acids.

[0006] There are multiple intramolecular parallel conformations, examples of which are shown in Figures 1 and 2. As shown in these drawings, quadruplex structures formed by the CMYC NHE region (nucleotide sequence shown in Table 1) include tetrads joined by loops, and the orientation of each strand contributing to the tetrads are predominantly parallel. In the conformations depicted in Figure 1, the four strands forming the tetrads are purely parallel (all four strands have a 5' to 3' orientation in the same direction). In contrast, the G-quadruplex conformations depicted in Figure 3 are purely antiparallel as the strand polarity sequentially alternates (*i.e.*, the orientation at positions 7 to 9 is South, the orientation at positions 11 to 13 or 12 to 14 is North, the orientation at positions 16 to 18 is South, and the orientation at positions 20 to 22 or 21 to 23 is North). The antiparallel conformations shown in Figure 3 conform to a folded-over hairpin, which often is referred to as a “chair” conformation. Like in Figure 1, intramolecular parallel structures are shown Figure 2. Three strands contributing to the tetrads of the two G-quadruplexes depicted in the middle of the drawing are parallel and one is antiparallel. The G-quadruplex depicted at the top right of Figure 2 also is intramolecular parallel, in which two parallel strands non-sequentially alternate with strands of reverse polarity (*i.e.*, the orientations at positions 12 to 14 and at positions 16 to 18 are the same). Data suggests that the three IP G-quadruplex conformations with mixed strand polarity in Figure 2 (*i.e.*, two depicted in the middle and one depicted at the top right) are particularly relevant structures for modulating the biological activity of certain nucleic acids by interaction with quadruplex-stabilizing compounds. Accordingly, the methods described herein are especially applicable to these three quadruplex conformations.

[0007] Thus, featured herein is a method for identifying a candidate molecule that interacts with a nucleic acid capable of forming a G-quadruplex structure, which comprises contacting a test molecule with a nucleic acid comprising or consisting of a G-quadruplex in an IP

conformation, and determining whether a portion of the test molecule is in proximity to and/or interacts with one or more sites in the G-quadruplex. Sites with which the test molecule interact often are proximally oriented G-tetrads, and sometimes are within one or more bases in a loop region. Multi-functional test molecules sometimes interact with other portions of the nucleic acid, such as with a site in the G-quadruplex and a site in a secondary structure formed by an i-motif sequence (*i.e.*, a sequence complementary to the G-quadruplex forming sequence) and/or a duplex region located between G-quadruplex and i-motif structures. A test molecule having a portion in proximity to the site in the G-quadruplex is identified as a candidate molecule that modulates the biological activity of the nucleic acid. The method also is useful for identifying a candidate molecule that modulates a biological activity of the nucleic acid capable of forming a G-quadruplex structure.

[0008] Also featured are methods for determining whether a candidate molecule modulates a biological activity of the nucleic acid comprising an IP quadruplex. In certain embodiments, an assay useful for monitoring the IP quadruplex structure is utilized (*e.g.*, chemical footprinting and/or circular dichroism assays). In specific embodiments, one or more nucleotides in the IP quadruplex are substituted with a fluorescent molecule (*e.g.*, 2-amino adenosine) and structurally distinct forms of the labeled nucleic acid are detected under various conditions (*e.g.*, by a gel electrophoresis mobility shift assay), or interactions between the labeled nucleic acid and other molecules are detected (*e.g.*, by monitoring shifts in fluorescence when test molecules and other molecules are added to a sample containing the labeled nucleic acid).

[0009] In addition, provided are methods for stabilizing an IP G-quadruplex conformation in a nucleic acid, which comprises contacting a system with a quadruplex-interacting molecule, whereby the molecule stabilizes the nucleic acid in an IP G-quadruplex conformation. The quadruplex interacting molecule sometimes selectively stabilizes an IP conformation over a non-IP quadruplex conformation, and sometimes selectively stabilizes one IP conformation over another IP conformation. In certain embodiments, the quadruplex interacting molecule is one set forth in U.S. application no. 10/661,241 filed September 12, 2003, and in other embodiments, the molecule is TMPyP4, an expanded porphoryin analog such as Se2SAP, or telomestatin, or a derivative thereof. Examples of other quadruplex-interacting molecules are described hereafter. Such processes can be performed in a cell-free system or in a system having cells (*e.g.*, in a cell culture dish or in an animal or human). Also featured are methods for treating a condition by administering a candidate molecule to a subject in need thereof.

Brief Description of the Drawings

[0010] Figure 1 depicts in the top row G-quadruplex IP structural conformations in a nucleic acid from the *CMYC* NHE region, which are useful for identifying candidate molecules that modulate the biological activity of the nucleic acid. All four strands contributing to the G-tetrad core have parallel polarities. The IP conformations are distinguished by different nucleosides in loop regions (e.g., the thymidine at position 10 and the guanosine at position 11 in the third structure from the left) and tetrad regions (e.g., the guanosine at position 13 in the second structure from the left and the guanosine at position 14 in the third structure from the left).

[0011] Figure 2 shows G-quadruplex structural conformations in a nucleic acid from the *CMYC* NHE region stabilized by quadruplex-interacting molecules. The conformation designated “parallel” on the left side of the drawing is an IP structure depicted in Figure 1. The conformations depicted in the middle top and bottom of the drawing are IP conformations with three parallel strands and one antiparallel strand. The conformations in the middle top and bottom are distinguished by the orientation of particular strands forming the tetrad core, as well as the orientation of loops containing the thymidine at position 10 and the thymidine at position 19. The conformation depicted on the right side of the drawing is intramolecular antiparallel, in which two parallel strands non-sequentially alternate with strands of reverse polarity.

[0012] Figure 3 depicts intramolecular antiparallel conformations that may form upon addition of a quadruplex interacting molecule. The antiparallel conformations shown form a folded-over hairpin structure referred to herein as a “chair.”

Detailed Description

[0013] Featured herein are methods for identifying a candidate molecule that interacts with a nucleic acid capable of forming a G-quadruplex IP structure. Such methods are useful for identifying molecules that modulate the biological activity of the nucleic acid by narrowing the number of molecules screened in biological assays. Such methods also are useful for designing molecules that modulate a biological activity of the nucleic acid. The compounds identified by the methods described herein are useful for identifying molecular therapeutics that reduce cell proliferation and/or microbial (e.g., bacterial or viral) proliferation, and in certain embodiments, treat a condition associated with the G-quadruplex in a subject.

Nucleic Acids

[0014] Candidate molecules are identified by contacting a test molecule with a nucleic acid and determining whether the test molecule interacts with the nucleic acid and/or modulates a biological activity of the nucleic acid. Nucleic acids often comprise or consist of DNA (e.g., genomic DNA (gDNA) or complementary DNA (cDNA)) or RNA (e.g., mRNA, tRNA, and rRNA). In embodiments where a nucleic acid is a gDNA or cDNA fragment, the fragment often is 50 or fewer, 100 or fewer, or 200 or fewer base pairs in length, and sometimes is about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, or about 1400 base pairs in length. In an embodiment, the nucleic acid is double-stranded, and is sometimes between about 30 nucleotides to about 40 nucleotides in length. Methods for generating gDNA and cDNA fragments are known in the art (e.g., gDNA may be fragmented by shearing methods and cDNA fragment libraries are commercially available). In embodiments where the nucleic acid is a synthetically prepared fragment nucleic acid, often referred to as an “oligonucleotide,” the fragment sometimes is less than 30, less than 40, less than 50, less than 60, less than 70, less than 80, less than 90, or less than 100 nucleotides in length. Synthetic oligonucleotides can be synthesized using standard methods and equipment, such as by using an ABI™3900 High Throughput DNA Synthesizer, which is available from Applied Biosystems (Foster City, CA).

[0015] Nucleic acids sometimes comprise or consist of analog or derivative nucleic acids, such as peptide nucleic acids (PNA) and others exemplified in U.S. Patent Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WIPO publications WO 00/56746 and WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above, in U.S. Patent Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; and in WO 00/75372.

[0016] The nucleic acids often include a nucleotide sequence capable of forming a secondary structure. Examples of secondary structures are quadruplex structures, which form from subsequences rich in purines (e.g., guanines in G-quadruplex structures), and i-motif structures, which form from subsequences rich in pyrimidines (e.g., cytosines). Secondary structures can exist in different conformations, which differ in strand stoichiometry and/or strand orientation. For example, secondary structures sometimes are formed by interstrand interactions, in which the interacting strands are in the same direction (*i.e.*, parallel, the interacting strands are oriented 5' to 3') or in different directions (*i.e.*, antiparallel, the

interacting strands are oriented 5' to 3' and 3' to 5'), and sometimes are formed by intrastrand interactions, examples of the latter of which are described in Figure 1. Quadruplex structures sometimes form because certain purine rich strands are capable of engaging in a slow equilibrium between a typical duplex helix structure and both unwound and non-B-form substructures. These unwound and non-B forms sometimes are referred to as "paranemic structures," and some forms are associated with sensitivity to S1 nuclease digestion, which sometimes are referred to as "nuclease hypersensitivity elements" or "NHEs." A quadruplex is one type of paranemic structure and certain NHEs can adopt a quadruplex structure. The entire length of the nucleic acid sometimes participates in the quadruplex structure, and a portion of the nucleic acid length (*i.e.*, a subsequence) often forms a quadruplex structure.

[0017] The ability of guanine-rich nucleic acids of adopting G-quadruplex conformations is due to the formation of guanine tetrads through Hoogsteen hydrogen bonds. One nucleic acid sequence can give rise to different quadruplex orientations, where the different conformations depend upon conditions under which they form, such as the concentration of potassium ions present in the system and the time that the quadruplex is allowed to form. Different quadruplex conformations can be distinguished from one another using standard procedures such as chemical footprinting and circular dichroism analyses (*see e.g.*, U.S. application no. 10/407,449 filed April 4, 2003). Also, multiple conformations can be in equilibrium with one another, and can be in equilibrium with a duplex conformation if a complementary strand exists in the system. For example, the IP conformations described herein may be in equilibrium with a chair conformation (*i.e.*, the latter conformation having bridging loops running orthogonal to two parallel loops and resulting from the simple folding-over of a DNA G-hairpin) or a basket conformation. The equilibrium may be shifted to favor one conformation over another such that the favored conformation is present in a higher concentration or fraction over the other conformation or other conformations. A certain conformation also may be trapped, for example, by selectively binding one conformation over others by a compound that stabilizes the particular conformation. The terms "favor" and "trap" as used herein refer to one conformation being at a higher concentration or fraction relative to other conformations, and also refer to stabilizing the particular quadruplex conformation. The terms "hinder" or "non-trapped" as used herein refer to one conformation being at a lower concentration with respect to other conformations. One conformation may be favored or trapped over another conformation if it is present in the system at a fraction of 50% or greater, 75% or greater, or 80% or greater or 90% or greater with respect to another conformation (*e.g.*, another quadruplex conformation, another paranemic

conformation, or a duplex conformation). Conversely, one conformation may be hindered or not trapped if it is present in the system at a fraction of 50% or less, 25% or less, or 20% or less and 10% or less, with respect to another conformation.

[0018] Equilibrium can be shifted to favor one quadruplex form over another by employing a variety of methods. For example, certain bases in a quadruplex nucleic acid may be mutated to prevent the formation of one conformation. Typically, these mutations are located in tetrad regions of the quadruplex (i.e., regions in which four bases interact with one another in a planar orientation). Also, ion concentrations and the time with which a quadruplex nucleic acid is contacted with certain ions can favor one conformation over another. For example, potassium ions stabilize quadruplex structures, and higher concentrations of potassium ions and longer contact times of potassium ions with a quadruplex nucleic acid can favor one conformation over another. A particular quadruplex conformation, such as IP and chair conformations, can be favored with contact times of 5 minutes or less in solutions containing 100 mM potassium ions, and often 10 minutes or less, 20 minutes or less, 30 minutes or less, and 40 minutes or less. Basket conformations typically require longer contact times with potassium ions. Potassium ion concentration and the counter anion can vary, and the specific quadruplex conformations existing for a given set of conditions can be determined. Furthermore, different quadruplex structures may be distinguished, trapped and favored by probing them with molecules that favorably interact with one quadruplex form over another (e.g., TMPyP4 binds with a higher affinity to chair structures as opposed to basket and IP structures). Quadruplex-interacting compounds sometimes bind with higher affinity to particular quadruplex structures *in vitro* than *in vivo* (e.g., the compound telomestatin binds to IP and chair structures *in vitro* but more favorably to chair structures *in vivo*).

[0019] Particular nucleotide sequences in a nucleic acid sometimes direct the type of secondary structure or structures that the nucleic acid is capable of adopting. For example, nucleic acid sequences conforming to the motif $(G_aX_b)_cG_a$ sometimes form an intramolecular IP or antiparallel G-quadruplex structure. Sometimes a is an integer between 2 and 6 and b is an integer between 1 and 4, and often, b is the integer 2 or 3. A nucleic acid often includes one or more flanking nucleotides on the 5' and/or 3' end of the nucleotide sequence that forms the quadruplex and are not part of the quadruplex structure. These motifs can be used to identify other quadruplex-forming sequences in regions of a genome operably linked to a gene. G-quadruplexes formed by sequences conforming to this motif sometimes include 2 to 6 G-tetrads, and often include between 3 and 5 G-tetrads.

[0020] Sometimes, a nucleic acid capable of forming one or more secondary structures includes a nucleotide sequence identical to a native nucleotide sequence present in genomic DNA. For example, a nucleic acid often comprises or sometimes consists of a nucleotide sequence or a portion of a nucleotide sequence set forth in Table 1. The nucleotide sequences in Table 1 originate from regions in genomic DNA that are capable of forming a quadruplex structure, which can regulate transcription of the *CMYC*, *PDGFA*, *PDGFB/c-sis*, *c-ABL*, *RET*, *BCL-2*, Cyclin *D1/BCL-1*, *KRAS*, *HRAS* and *VEGF*.

TABLE 1

Sequence	SEQ ID NO	Origin
TG ₄ AG ₃ TG ₄ AG ₃ TG ₄ AAGG	1	<i>CMYC</i>
G ₁₃ CG ₅ CG ₅ CG ₅ AG ₄ T	2	<i>PDGFA</i>
G ₈ ACGCG ₃ AGCTG ₅ AG ₃ CTTG ₄ CCAG ₃ CG ₄ CGCTTAG ₅	3	<i>PDGFB/c-sis</i>
AGGAAG ₄ AG ₃ CCG ₆ AGGTGGC	4	<i>c-ABL</i>
G ₅ (CG ₄) ₃	5	<i>RET</i>
G ₃ AGGAAG ₅ CG ₃ AGTCG ₄	6	<i>BCL-2</i>
G ₄ ACGCG ₃ CG ₅ CG ₆ AG ₃ CG	7	Cyclin D1/ <i>BCL-1</i>
(G ₃ A) ₃ AGGA(G ₃ A) ₄ GC	8	<i>K-RAS</i>
G ₅ (CG ₄) ₃	9	<i>H-RAS</i>
C ₃ G ₄ CG ₃ C ₂ G ₅ CG ₄ TC ₃ G ₂ CG ₅ CG ₂ AG	10	<i>VEGF</i>

While quadruplex forming sequences typically are identified in regulatory regions upstream of a gene (e.g., a promoter or a 5' untranslated region (UTR)), quadruplex forming sequences also may be identified within a 3' UTR or within an intron or exon of a gene.

[0021] A nucleic acid sometimes includes a nucleotide sequence similar to or substantially identical to a native nucleotide sequence. A similar or substantially identical nucleotide sequence may include modifications to the native sequence, such as substitutions, deletions, or insertions of one or more nucleotides. The substantially identical sequence sometimes conforms

to the $(G_aX_b)_cG_a$ motif described above. The term "substantially identical" refers to two or more nucleic acids sharing one or more identical nucleotide sequences. Included are nucleotide sequences that sometimes are 55%, 60%, 65%, 70%, 75%, 80%, or 85% identical to a native quadruplex-forming nucleotide sequence, and often are 90% or 95% identical to the native quadruplex-forming nucleotide sequence (each identity percentage can include a 1%, 2%, 3% or 4% variance). One test for determining whether two nucleic acids are substantially identical is to determine the percentage of identical nucleotide sequences shared between the nucleic acids.

[0022] Calculations of sequence identity can be performed as follows. Sequences are aligned for optimal comparison purposes and gaps can be introduced in one or both of a first and a second nucleic acid sequence for optimal alignment. Also, non-homologous sequences can be disregarded for comparison purposes. The length of a reference sequence aligned for comparison purposes sometimes is 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70%, 80%, 90%, 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions then are compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the nucleotides are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

[0023] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS* 4:11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http address www.gcg.com), using a NWGapDNA.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blossum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.

[0024] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As used herein, the term "stringent conditions" refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the

art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y., 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. Also, stringency conditions include hybridization in 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0025] Also, nucleotide sequences of native quadruplex-forming nucleotide sequences may be used as "query sequences" to perform a search against public databases to identify related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.*, *J. Mol. Biol.* 215:403-410 (1990). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain homologous nucleotide sequences. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul, *et al.*, *Nucleic Acids Res.* 25(17):3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see*, [http address www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).

Contacting Nucleic Acids with Test Molecules

[0026] The nucleic acid is contacted with a test molecule, the latter of which is described in further detail hereafter, in a variety of manners. In certain embodiments, a physical representation of the nucleic acid and the test molecule is contacted and interactions between the physical representations are observed. In other embodiments, a representation of the nucleic acid is contacted with a representation of a test molecule on paper or *in silico* (*i.e.*, in a computer environment).

[0027] In *in silico* processes, three-dimensional representations of the nucleic acid and the test molecule often are brought into proximity with one another. The three dimensional representations of the nucleic acid and the test molecule are oriented with one another to

maximize favorable interactions (e.g., ionic interactions, hydrogen bonds and/or hydrophobic interactions) and minimize unfavorable interactions (e.g., steric clashes) between portions of the test molecule and portions of the nucleic acid, which minimizes the energy of the complex. The contacting process sometimes is performed manually (e.g., the orientation of three-dimensional representations of the nucleic acid and the test molecule are manipulated on a computer by a user), sometimes is accomplished in an automated manner using computer software (e.g., the software docks the three-dimensional representations of the nucleic acid and the test molecule and then energy minimizes the resulting structures), and often is accomplished by a combination of a manual and automated method. Commercially available computer software is available for carrying out these processes (see, e.g., AutoDock, DOCK, Dock/InsightII, FlexX, MULTIDOCK, FTDOCK and GRAMM computer programs; see also http address www.molvis.chem.indiana.edu/app_guide/ for other computer programs useful for visualizing three dimensional representations of molecules and manipulating them). Using such software, the test molecule sometimes is part of a molecular library from which a computer program often samples test molecules iteratively and docks them with a nucleic acid. In other embodiments, a computer program is utilized to build test molecules having portions that meet specific criteria. In an example of the latter embodiments, a test molecule can be built by specifying that a hydrophobic moiety must be in proximity to a duplex region located between a G-quadruplex structure and an i-motif and also specify that a moiety capable of hydrogen bonding with nucleotides in a G-quadruplex structure be present and specifically oriented in the test molecule.

[0028] The nucleic acid sometimes is contacted with a nucleic acid binding protein *in silico* by docking three-dimensional renditions of the two molecules to one another.

Three-dimensional renditions of test molecules sometimes are contacted with the three-dimensional rendition of the docked nucleic acid/protein structure and sometimes the test molecule or candidate molecule is contacted with the undocked nucleic acid and/or binding protein before the nucleic acid and protein are docked to one another. In an embodiment, the nucleic acid comprises or consists of a structure set forth in Figure 1. In another embodiment, the nucleic acid is contacted with one or more nucleic acid binding protein, such as NM23-H2 (see e.g., deposit reference 1NUE at http address rutgers.rcsb.org/pdb/ for coordinates of a three-dimensional representation of an NM23-H2 protein) and/or another nucleic acid binding protein (e.g., CNBP, hnRNP κ or Sp1). In certain embodiments, the nucleic acid is docked with a portion of a nucleic acid binding protein before, during, or after the nucleic acid and/or the nucleic acid binding protein portion are contacted with a test molecule or candidate molecule.

[0029] Based in part upon the proximity of specific atoms in the test molecule and in the nucleic acid (*e.g.*, distance between the atoms), it can be determined whether one or more atoms in the test molecule and in the nucleic acid interact with one another. Atoms in the two molecules can interact with one another to form hydrogen bond interactions, Van der Waals interactions, ionic interactions, and hydrophobic interactions, for example. A portion of a test molecule often is in proximity to a site in the nucleic acid molecule when the closest atoms in the two molecules are within a distance of about 8 Å from one another, about 5 Å from one another, about 4 Å from one another, about 3 Å from one another, about 2 Å from one another, about 1 Å from one another, or about 0.5 Å from one another. The molecules sometimes are determined as being in proximity to one another based upon a relative distance, where the distance between an atom in the test molecule and an atom at a site of the nucleic acid is closer to one another than the distance between other test molecule atoms and nucleotide atoms.

[0030] Candidate molecules are selected from test molecules meeting certain criteria. In an embodiment, one criterion is that a portion of the test molecule is in proximity to a site and optionally interacts with a site comprising one or more atoms of a nucleoside in a G-tetrad of the G-quadruplex IP structure. For example, a portion of the test molecule may be in proximity and optionally interact with a portion of a guanosine in a tetrad, such as a tetrad formed by guanosines at positions 9, 13, 14, 18, 22, 23 or positions 7, 11, 12, 16, 20, 21 or a combination thereof in the IP quadruplex structures of Figure 1. A portion of the test molecule also may be in proximity to and optionally interact with one or more atoms in a nucleoside located in a loop region (*e.g.*, an atom in a thymidine at position 10, a guanosine at position 11, a guanosine at position 14, an adenose at position 15, a thymidine at position 19, a guanosine at position 20, or a combination thereof in the loop regions of the G-quadruplex IP structures in Figure 1), and sometimes, may be in proximity to or optionally interact with one or more atoms in a nucleoside not in a loop or tetrad (*e.g.*, an adenose at position 6 or a guanosine at position 23 in Figure 1).

[0031] Of the intramolecular parallel conformations having three parallel strands and one antiparallel strand, a portion of the test molecule may be in proximity to and optionally interact with one or more atoms of a tetrad guanosine, such as a guanosine in a tetrad at position 7, 13, 18 or 22; 9, 13, 18 or 20; 9, 11, 16 or 20; or 7, 11, 16 or 22 as shown in Figure 2 or the like. For the latter G-quadruplex conformations, a portion of the test molecule may be in proximity to and optionally interact with one or more atoms of a loop nucleoside, such as a thymidine at position 10, a guanosine at position 11, an adenose at position 15, a thymidine at position 19, and a

guanosine at position 20, and sometimes, may be in proximity to or optionally interact with one or more atoms in a nucleoside not in a loop or tetrad, such as an adenose at position 6.

[0032] Of intramolecular G-quadruplex conformations having mixed strand polarity, such as the conformation shown on the right of Figure 2 and the like, a portion of the test molecular may in proximity to and optionally interact with one or more atoms of a tetrad guanosine, such as a guanosine in a tetrad at position 7, 14, 18 or 21 or position 9, 12, 16 or 23. A portion of the test molecule also may be in proximity to and optionally interact with one or more atoms in a nucleoside located in a loop region (e.g., an atom in a thymidine at position 10, a guanosine at position 11, an adenose at position 15, a thymidine at position 19, a guanosine at position 20, or a combination thereof), and sometimes, may be in proximity to or optionally interact with one or more atoms in a nucleoside not in a loop or tetrad (e.g., an adenose at position 6).

[0033] The methods described herein also are applicable to intramolecular antiparallel conformations, such as those shown in Figure 3 and the like. A portion of a test molecule may be in proximity to and optionally interact with one or more atoms in a tetrad guanosine, such as a guanosine in a tetrad at position 7, 13, 16 or 22; 7, 13, 16 or 23; 7, 14, 16 or 22; 7, 14, 16 or 23; 9, 11, 18 or 20; 9, 11, 18 or 21; 9, 12, 18 or 20; or 9, 12, 18 or 21. A portion of the test molecule may be in proximity to and optionally interact with one or more atoms of a loop nucleoside in an intramolecular antiparallel structure, such as a thymidine at position 10, a guanosine at position 11, a guanosine at position 14, an adenose at position 15, a thymidine at position 19 and/or a guanosine at position 20, and sometimes, may be in proximity to or optionally interact with one or more atoms in a nucleoside not in a loop or tetrad, such as an adenose at position 6 or a guanosine at position 23.

[0034] Nucleic acid subsequence having sufficient guanosines to form G-quadruplex tetrads can be aligned to form the conformations depicted in Figure 1 and Figure 2, even where the nucleotide subsequence differs from the *CMYC* NHE region subsequence and the nucleosides and number of nucleosides not forming the tetrad core differ. For example, nucleotide subsequences having sufficient guanosines to form G-tetrads in a quadruplex, such as those shown in Table 1, can be assembled into the nucleic acid configurations shown in Figures 1 and 2.

[0035] Test molecules that interact with more than one atom in a nucleoside participating in a G-tetrad or a loop often are identified as candidate molecules. In addition to interacting with atoms in a G-quadruplex, a candidate molecule sometimes interacts with one or more atoms in an adjacent secondary structure. An adjacent secondary structure sometimes is formed by an

i-motif complementary to the nucleotide sequence that forms the G-quadruplex. In other embodiments, the adjacent secondary structure is formed from a nucleotide sequence located upstream or downstream of the same strand having the G-quadruplex-forming nucleotide sequence that interacts with the G-quadruplex (e.g., a silencer sequence in association with a G-quadruplex formed by a nucleotide sequence located 5' of the PDGF receptor open reading frame; see e.g., U.S. application no. 60/425,869 filed November 12, 2002). The candidate molecule sometimes forms one or more hydrogen bonds and/or sometimes forms a hydrophobic interaction (e.g., end-stacks or intercalates) with one or more atoms in a G-quadruplex structure and/or an adjacent secondary structure. A portion of a candidate molecule sometimes forms a hydrogen bond and/or intercalates with one or more atoms in a duplex region flanking the G-quadruplex and/or the adjacent secondary structure.

[0036] In addition to interactions with one IP quadruplex conformation, a candidate molecule sometimes interacts with another G-quadruplex conformation, such as another IP conformation or an intramolecular antiparallel conformation. In certain embodiments, a candidate molecule interacts with a nucleic acid when the latter is in an IP quadruplex conformation having four parallel strands contributing to the tetrad core and in an IP quadruplex conformation having two or three parallel strands contributing to the tetrad core. In another embodiment, the candidate molecule interacts with an IP quadruplex conformation having four parallel strands with a lower affinity than an IP quadruplex conformation having two or three parallel strands. In another embodiment, a candidate molecule identified as interacting with an IP quadruplex is tested to determine whether it can interact with a non-IP quadruplex form or structure (e.g., antiparallel, basket, intermolecular).

[0037] Test molecules can be optimized to form specific interactions with one or more sites of the nucleic acid. For example, a test molecule can be designed or optimized to include a chemical moiety capable of forming an interaction with an epsilon-amino moiety from a lysine in the nucleic acid binding protein (e.g., lysine 12 in a subunit of NM23-H2), thereby inhibiting relaxation of secondary structures in the nucleic acid, inhibiting transcription of the *CMYC* gene, and inhibiting or reducing cell proliferation. In the latter embodiment, such an inhibitor sometimes acts as a suicide inhibitor which traps the binding protein in an unproductive conformation. The test molecule also can be designed or optimized to include portions that interact with the G-quadruplex structure and/or an i-motif structure and optionally to include a moiety that intercalates with the intermediate duplex region or part of the duplex region.

Intercalation moieties often are hydrophobic and examples of such moieties are known (e.g., ethidium bromide and other moieties described below).

Test Molecules and Candidate Molecules

[0038] The nucleic acid is contacted with one or more test molecules to identify candidate molecules that modulate a biological activity of the nucleic acid. Molecules often are organic or inorganic compounds having a molecular weight of 10,000 grams per mole or less, and sometimes having a molecular weight of 5,000 grams per mole or less, 1,000 grams per mole or less, or 500 grams per mole or less. Also included are salts, esters, and other pharmaceutically acceptable forms of the compounds. Compounds that interact with nucleic acids are known in the art (see, e.g., Hurley, *Nature Rev. Cancer* 2:188–200 (2002); Anantha, *et al.*, *Biochemistry* Vol. 37, No. 9:2709-2714 (1998); and Ren, *et al.*, *Biochemistry* 38:16067-16075 (1999)).

[0039] Compounds can be obtained using known combinatorial library methods, including spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; “one-bead one-compound” library methods; and synthetic library methods using affinity chromatography selection. Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90:6909 (1993); Erb, *et al.*, *Proc. Natl. Acad. Sci. USA* 91:11422 (1994); Zuckermann, *et al.*, *J. Med. Chem.* 37:2678 (1994); Cho, *et al.*, *Science* 261:1303 (1993); Carell, *et al.*, *Angew. Chem. Int. Ed. Engl.* 33:2059 (1994); Carell, *et al.*, *Angew. Chem. Int. Ed. Engl.* 33:2061 (1994); and Gallop, *et al.*, *J. Med. Chem.* 37:1233 (1994).

[0040] In addition to an organic and inorganic compound, a molecule sometimes is a nucleic acid, a catalytic nucleic acid (e.g., a ribozyme), an inhibitory RNA (RNAi or siRNA), a nucleotide, a nucleotide analog, a polypeptide, an antibody, or a peptide mimetic. Methods for making and using these molecules are known. For example, methods for making ribozymes and assessing ribozyme activity are described (see e.g., U.S. Patent Nos. 5,093,246; 4,987,071; and 5,116,742; Haselhoff & Gerlach, *Nature* 334:585-591 (1988) and Bartel & Szostak, *Science* 261:1411-1418 (1993)). Also, methods for generating siRNA are known (see e.g., Elbashir, *et al.*, *Methods* 26:199-213 (2002) and http address www.dharmacon.com) and peptide mimetic libraries are described (see, e.g., Zuckermann, *et al.*, *J. Med. Chem.* 37:2678-2685 (1994)).

[0041] Candidate molecules sometimes meet the following structural and chemical criteria. A candidate molecule sometimes interacts with one region of the nucleic acid or the nucleic acid binding protein, and sometimes interacts with two or more regions of the nucleic acid and/or the

nucleic acid binding protein (*e.g.*, the candidate molecule can interact with two or more regions in the nucleic acid or nucleic acid binding protein, or can interact with a region in the nucleic acid and a region in the nucleic acid binding protein). Each molecule sometimes includes a moiety that interacts with a G-quadruplex structure, an i-motif structure and/or a duplex structure of the nucleic acid, and/or an amino acid of the nucleic acid binding protein. In an embodiment, a moiety in the molecule is capable of end-stacking with or intercalating between one or more G-tetrads of a G-quadruplex, such as a moiety comprising a planar or polycyclic structure, for example. Examples of such moieties are anthraquinone, acridone, napthyl, pheoxazine, xanthone, benzoxazole, phenathiazine, phenazine, benzothiazole, acridine, dibenzofuran, benzimidazole, fluorenone, fluorene, and phenanthroline. In another embodiment, a moiety is a duplex DNA intercalator, capable of binding to a duplex DNA region adjacent to a secondary structure in the nucleic acid, such as a moiety having a planar or polycyclic structure (*e.g.*, an intercalator listed previously). In a related embodiment, the moiety is capable of groove-binding to a duplex region in the nucleic acid, such as a polypeptide or sugar-based moiety capable of groove binding. In other embodiments, a moiety is capable of binding to an amino acid of a nucleic acid binding protein (*e.g.*, NM23 protein), such as a nucleotide or a nucleotide mimetic, or a carbonyl-, acetal-, or imine-containing moiety. Molecules having quadruplex-interacting moieties are disclosed in application no. 10/407,449 filed April 4, 2003; application no. 10/660,897 filed September 11, 2003; application no. 10/661,241 filed September 12, 2003; application no. 60/463,171 filed April 15, 2003 and application no. 60/461,205 filed April 7, 2003.

[0042] Each molecule that interacts with two or more target regions in a nucleic acid and/or a nucleic acid binding protein sometimes comprises two or more moieties that independently interact with the target regions and are joined by a linker. A linker joining the moieties sometimes is 7.5 Å to 40 Å in length, sometimes comprises between 5 and 20 atoms, often is flexible, and sometimes is constrained (*e.g.*, in a conformation that follows the groove of duplex DNA). The linker sometimes comprises polyamide or polysaccharide moieties (*e.g.*, comprising amino saccharide units), and sometimes includes known linkage functionalities such as those independently selected from amide, ester, ether, amine, sulfide, sulfonamide, alkyl or aryl, for example.

[0043] Featured herein is structural information descriptive of the candidate molecules and therapeutics identified by the processes described herein as modulating the biological activity of a nucleic acid capable of adopting a G-quadruplex IP conformation. As described above, the

candidate molecule or therapeutic may modulate the biological activity by interacting with G-quadruplexes in other conformations, such as the chair conformation for example. In certain embodiments, information descriptive of candidate molecule structure (e.g., chemical formula or sequence information) sometimes is stored and/or renditioned as an image or as three-dimensional coordinates. The information often is stored and/or renditioned in computer readable form and sometimes is stored and organized in a database. In certain embodiments, the information may be transferred from one location to another using a physical medium (e.g., paper) or a computer readable medium (e.g., optical and/or magnetic storage or transmission medium, floppy disk, hard disk, random access memory, computer processing unit, facsimile signal, satellite signal, transmission over an internet or transmission over the world-wide web).

Biological Activity of Candidate Molecules

[0044] Determining whether the biological activity of a native quadruplex DNA is modulated in a cell, tissue, or organism can be accomplished by monitoring modulation of a signal in an *in vitro* or *in vivo* assay. The signal in the assay sometimes is generated or modulated by transcription of the nucleic acid, binding of a protein to the nucleic acid (e.g., NM23-H2), a fluorophore incorporated in the nucleic acid, or cell proliferation, for example. Transcription can be detected, for example, by directly detecting RNA transcripts or detecting polypeptides translated by transcripts, which are methods known in the art.

[0045] Candidate molecules, some identified by the procedures described herein, sometimes are screened in *in vitro* or *in vivo* assays to determine whether they modulate the biological activity of the nucleic acid. Candidate molecules and nucleic acids can be added to an assay system in any order to determine whether the candidate molecule modulates the biological activity of the nucleic acid. For example, a candidate molecule sometimes is added to an assay system before, simultaneously, or after a nucleic acid is added.

[0046] In these assays, candidate molecules are contacted with the nucleic acid in the assay system, where the term "contacting" refers to placing a candidate molecule in close proximity to a nucleic acid and allowing the assay components to collide with one another, often by diffusion. Contacting these assay components with one another can be accomplished by adding them to a body of fluid or in a reaction vessel, for example. The components in the system may be mixed in variety of manners, such as by oscillating a vessel, subjecting a vessel to a vortex generating apparatus, repeated mixing with a pipette or pipettes, or by passing fluid containing one assay component over a surface having another assay component immobilized thereon, for example.

[0047] As used herein, the term "system" refers to an environment that receives the assay components, which includes, for example, microtiter plates (e.g., 96-well or 384-well plates), silicon chips having molecules immobilized thereon and optionally oriented in an array (see, e.g., U.S. Patent No. 6,261,776 and Fodor, *Nature* 364:555-556 (1993)), and microfluidic devices (see, e.g., U.S. Patent Nos. 6,440,722; 6,429,025; 6,379,974; and 6,316,781). The system can include attendant equipment for carrying out the assays, such as signal detectors, robotic platforms, and pipette dispensers.

[0048] One or more assay components (e.g., the nucleic acid, candidate molecule or nucleic acid binding protein) sometimes are immobilized to a solid support. The attachment between an assay component and the solid support often is covalent and sometimes is non-covalent (see, e.g., U.S. Patent No. 6,022,688 for non-covalent attachments) and the attachment sometimes is by a linking moiety. The solid support often is one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a bead (see, e.g., Lam, *Nature* 354: 82-84 (1991)) optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are known (see, e.g., U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0049] Protein molecules sometime are contacted with the nucleic acid. Polypeptide molecules sometimes are added to the system in free form, and sometimes are linked to a solid support or another molecule. For example, polypeptide test molecules sometimes are linked to a phage via a phage coat protein. The latter embodiment often is accomplished by using a phage display system, where nucleic acids linked to a solid support are contacted with phages that display different polypeptide candidate molecules. Phages displaying polypeptide candidate molecules that interact with the immobilized nucleic acids adhere to the solid support, and phage nucleic acids corresponding to the adhered phages then are isolated and sequenced to determine the sequence of the polypeptide test molecules that interacted with the immobilized nucleic acids. Methods for displaying a wide variety of peptides or proteins as fusions with bacteriophage coat proteins are known (Scott and Smith, *Science* 249:386-390 (1990); Devlin, *Science* 249:404-406 (1990); Cwirla, *et al.*, *Proc. Natl. Acad. Sci.* 87:6378-6382 (1990); Felici, *J. Mol. Biol.* 222:301-310 (1991); U.S. Patent Nos. 5,096,815 and 5,198,346; U.S. Patent Nos. 5,223,409; 5,403,484; 5,571,698; and 5,766,905). Methods also are available for linking the test polypeptide to the N-terminus or the C-terminus of the phage coat protein.

[0050] A signal generated by the system when a candidate molecule binds to a nucleic acid and/or a nucleic acid binding protein often scales directly with a range of increasing nucleic acid, nucleic acid binding protein, or candidate molecule concentrations. Signal intensity often exhibits a hyperbolic relationship when plotted as a function of nucleic acid, candidate molecule, or nucleic acid binding protein concentrations. The signal sometimes is increased relative to background signal levels when a candidate molecule binds to a nucleic acid and/or a nucleic acid binding protein, and sometimes the signal decreases relative to background signal levels under such circumstances. The candidate molecules often interact with the nucleic acid and/or nucleic acid binding protein by reversible binding, and sometimes interact with irreversible binding. For example, the candidate molecule may reversibly form a covalent bond between a portion of the candidate molecule and an amino acid side chain in the protein (*e.g.*, a lysine), depending on the chemical structure of the candidate molecule.

[0051] Candidate molecules often are identified as interacting with the nucleic acid and/or nucleic acid binding protein when the signal produced in a system containing the candidate molecule is different than the signal produced in a system not containing the candidate molecule. While background signals may be assessed each time a new candidate molecule, nucleic acid, or nucleic acid binding protein is probed by the assay, detecting the background signal often is not required each time a new test molecule or test nucleic acid is assayed. Control assays also can be performed to determine background signals and to rule out false positive results and false negative results. Such control assays often do not comprise one or more assay components included in other assays (*e.g.*, a control assay sample sometimes does not include a candidate molecule, a nucleic acid, or a protein that interacts with the nucleic acid).

[0052] In addition to determining whether a candidate molecule gives rise to a different signal, the affinity of the interaction between the candidate molecule with the nucleic acid and/or nucleic acid binding protein sometimes is quantified. IC₅₀, K_d, or K_i threshold values sometimes are compared to the measured IC₅₀ or K_d values for each interaction, and thereby are used to identify a candidate molecule that interacts with the nucleic acid or nucleic acid binding protein and modulates the biological activity. For example, IC₅₀ or K_d threshold values of 10 μM or less, 1 μM or less, and 100 nM or less often are utilized, and sometimes threshold values of 10 nM or less, 1 nM or less, 100 pM or less, and 10 pM or less are utilized to identify candidate molecules that interact with nucleic acids and/or binding proteins and modulate the biological activity.

[0053] Specific assays sometimes are utilized to identify candidate molecules that modulate the biological activity of a nucleic acid and/or binding protein complex. For example, fluorescence assays, gel mobility shift assays (see, e.g., Jin & Pike, *Mol. Endocrinol.* 10:196-205 (1996) and Postel, *J. Biol. Chem.* 274:22821-22829 (1999)), polymerase arrest assays, transcription reporter assays, DNA cleavage assays, protein binding and apoptosis assays (see, e.g., Amersham Biosciences (Piscataway, New Jersey)) sometimes are utilized. Also, topoisomerase assays sometimes are utilized subsequently to determine whether the quadruplex interacting molecules have a topoisomerase pathway activity (see, e.g., TopoGEN, Inc. (Columbus, Ohio)).

[0054] A fluorescence interaction assay is useful for identifying candidate molecules that interact with DNA capable of forming a quadruplex structure. In particular, such assays are useful in *in vitro* high-throughput assays and in gel electrophoretic mobility shift assays. Such methods sometimes comprise contacting a sample comprising a nucleic acid with a candidate molecule, where the nucleic acid includes or consists of nucleotide sequence that is identical or substantially similar to a native nucleotide sequence capable of forming a G-quadruplex structure. One or more nucleoside moieties in the native nucleotide sequence sometimes are substituted with a fluorescent nucleoside analog. Examples of such fluorescent nucleoside analogs are 2-amino purine (e.g., 2-amino adenosine), pyrrolo-C, 6-MAP, and furano-dT (for other examples, see http address www.glenresearch.com/GlenReports/GR15-13.html). In specific embodiments, one or more nucleoside moieties in a loop region of an IP structure in Figure 1 are substituted with a fluorescent nucleoside analog such as 2-amino purine or pyrrolo-C. A fluorescent signal generated by the sample is detected after the sample is contacted by the candidate molecule, and the test molecule is identified as a candidate molecule that interacts with the nucleic acid when the fluorescent signal detected before the sample is contacted with the test molecule differs from the fluorescent signal detected after the sample is contacted with the test molecule. Fluctuations sometimes are reduced fluorescence intensity at a particular wavelength, and sometimes are shifts in the wavelengths at which fluorescence is detected. Often, the labeled strand is hybridized with a complementary strand and any fluctuations in fluorescence are detected upon hybridization, and the labeled hybrid then is contacted with test molecules and fluctuations in fluorescence are detected to determine which of the test molecules interact with the labeled nucleic acid. In certain embodiments, the sample is contacted with a nucleic acid binding protein such as NM23-H2, Sp1, CNBP and/or hnRNP κ before, at the same time, or after the sample is contacted with the test molecule. In other embodiments, the labeled

nucleic acid is interacted with test molecules or proteins and the reaction products then are subjected to a gel electrophoretic mobility shift assay.

[0055] Another example of a fluorescence interaction assay is a system that includes a nucleic acid, a signal molecule, and a candidate or test molecule. The signal molecule generates a fluorescent signal when bound to the nucleic acid (e.g., N-methylmesoporphyrin IX (NMM)), and the signal is altered when a candidate compound competes with the signal molecule for binding to the nucleic acid. An alteration in the signal when a candidate molecule is present as compared to when the candidate molecule is not present identifies the candidate molecule as a nucleic acid-interacting molecule. 50 µl of nucleic acid is added in 96-well plate. A candidate molecule also is added in varying concentrations. A typical assay is carried out in 100 µl of 20 mM HEPES buffer, pH 7.0, 140 mM NaCl, and 100 mM KCl. 50 µl of the signal molecule NMM then is added for a final concentration of 3 µM. NMM is obtained from Frontier Scientific Inc, Logan, Utah. Fluorescence is measured at an excitation wavelength of 420 nm and an emission wavelength of 660 nm using a FluroStar 2000 fluorometer (BMG Labtechnologies, Durham, NC). Fluorescence often is plotted as a function of concentration of the candidate molecule or nucleic acid and maximum fluorescent signals for NMM are assessed in the absence of these molecules.

[0056] DNA cleavage assays are useful for determining at which sites of a nucleic acid a nucleic acid binding protein interacts, for example. DNA cleavage assays have been reported (e.g., Postel, *J. Biol. Chem.*, 274:22821-22829 (1999)). In general, a detectable label is incorporated at one portion of the nucleic acid and the label is separated from another portion of the nucleic acid having no detectable label or a different detectable label upon cleavage. Examples of detectable labels are known, such as fluorophores (e.g., Anantha, *et al.*, *Biochemistry* 37:2709-2714 (1998) and Qu & Chaires, *Methods Enzymol.* 321:353-369 (2000)), fluorescent nucleotide analogs described above, NMR spectral shifts (see, e.g., Arthanari & Bolton, *Anti-Cancer Drug Design* 14:317-326 (1999)), fluorescence resonance energy transfers (see, e.g., Simonsson & Sjöback, *J. Biol. Chem.* 274:17379-17383 (1999)), a radioactive isotope (e.g., ¹²⁵I, ¹³¹I, ³⁵S, ³²P, ¹⁴C or ³H); a light scattering label (see, e.g., U.S. Patent No. 6,214,560; Genicon Sciences Corporation, San Diego, CA); an enzymic or protein label (e.g., green fluorescent protein (GFP) or peroxidase), or another chromogenic label or dye. The nucleic acid also can be linked to two fluorophores for a fluorescence resonance energy transfer (FRET) assay, where one fluorophore emits light at a wavelength at which the other fluorophore is excited, where such fluorescence energy transfer occurs when the nucleic acid is intact and does

not occur when the nucleic acid is cleaved by a nucleic acid binding protein. Similarly, a candidate molecule linked to a nucleic acid binding protein can be detected by detecting the candidate molecule bound to the protein or a detectable label bound to a candidate molecule linked to a binding protein.

[0057] A gel electrophoretic mobility shift assay (EMSA) is useful for determining whether a nucleic acid forms a quadruplex and whether a nucleotide sequence is quadruplex destabilizing. EMSA is conducted as described previously (Jin & Pike, *Mol. Endocrinol.* 10:196-205 (1996)) with minor modifications. Synthetic single-stranded oligonucleotides are labeled in the 5' terminus with T4-kinase in the presence of [γ -³²P] ATP (1,000 mCi/mmol, Amersham Life Science) and purified through a sephadex column. ³²P-labeled oligonucleotides (~30,000 cpm) then are incubated with or without various concentrations of a testing compound in 20 μ l of a buffer containing 10 mM Tris pH 7.5, 100 mM KCl, 5 mM dithiothreitol, 0.1 mM EDTA, 5 mM MgCl₂, 10% glycerol, 0.05% Nonedit P-40, and 0.1 mg/ml of poly(dI-dC) (Pharmacia). After incubation for 20 minutes at room temperature, binding reactions are loaded on a 5% polyacrylamide gel in 0.25 x Tris borate-EDTA buffer (0.25 x TBE, 1 x TBE is 89 mM Tris-borate, pH 8.0, 1 mM EDTA). The gel is dried and each band is quantified using a phosphorimager.

[0058] Another example of an EMSA assay is performed as follows. Ten microliter reactions are assembled in Reaction Buffer (50 mM Tris-HCl, pH 7.9, 0.5 mM dithiothreitol, and 50 mg/ml bovine serum albumin). MgCl₂, KCl, EDTA, protease K, and ATP are added. Radiolabeled DNA or fluorescently labeled DNA (described above) and NM23-H2 in storage buffer (20 mM Hepes, pH 7.9, 5 mM MgCl₂, 0.1 mM EDTA, 0.1 M KCl, 1 mM dithiothreitol, 20% glycerol, and protease inhibitors (Postel, *et al.*, *Mol. Cell. Biol.* 9:5123-5133 (1989))) are added last, and the reactions are incubated for 15 minutes at room temperature. To separate the protein-DNA complexes, the reactions are loaded onto 5% native polyacrylamide gels and electrophoresed in 0.53 TBE buffer (45 mM Tris borate, pH 8.3, 1.25 mM EDTA) at room temperature for 30 minutes at 100 V. Gels are vacuum-dried and exposed onto XAR (Eastman Kodak Co.) film.

[0059] Chemical footprinting assays are useful for assessing quadruplex structure. Quadruplex structure is assessed by determining which nucleotides in a nucleic acid is protected or unprotected from chemical modification as a result of being inaccessible or accessible, respectively, to the modifying reagent. A DMS methylation assay is an example of a chemical footprinting assay. In such an assay, bands from EMSA are isolated and subjected to DMS-

induced strand cleavage. Each band of interest is excised from an electrophoretic mobility shift gel and soaked in 100 mM KCl solution (300 µl) for 6 hours at 4°C. The solutions are filtered (microcentrifuge) and 30,000 cpm (per reaction) of DNA solution is diluted further with 100 mM KCl in 0.1X TE to a total volume of 70 µl (per reaction). Following the addition of 1 µl salmon sperm DNA (0.1 µg/µl), the reaction mixture is incubated with 1 µl DMS solution (DMS:ethanol; 4:1; v:v) for a period of time. Each reaction is quenched with 18 µl of stop buffer (β -mercaptoethanol:water:NaOAc (3 M); 1:6:7; v:v:v). Following ethanol precipitation (twice) and piperidine cleavage, the reactions are separated on a preparative gel (16%) and visualized on a phosphorimager.

[0060] A polymerase arrest assay is useful for determining whether a candidate molecule stabilizes a quadruplex structure. Such an assay includes a template nucleic acid, which often comprises a quadruplex forming sequence, and a primer nucleic acid that hybridizes to the template nucleic acid 5' of the quadruplex-forming sequence. The primer is extended by a polymerase (e.g., Taq polymerase), which advances from the primer along the template nucleic acid. In this assay, a quadruplex structure can block or arrest the advance of the enzyme, leading to shorter transcription fragments. Also, the arrest assay may be conducted at a variety of temperatures, including 45°C and 60°C, and at a variety of ion concentrations. An example of a Taq polymerase stop assay is described in Han, *et al.*, *Nucl. Acids Res.* 27:537-542 (1999), which is a modification of that used by Weitzmann, *et al.*, *J. Biol. Chem.* 271, 20958–20964 (1996). Briefly, a reaction mixture of template DNA (50 nM), Tris-HCl (50 mM), MgCl₂ (10 mM), DTT (0.5 mM), EDTA (0.1 mM), BSA (60 ng), and 5'-end-labeled quadruplex nucleic acid (~18 nM) is heated to 90°C for 5 minutes and allowed to cool to ambient temperature over 30 minutes. Taq Polymerase (1 µl) is added to the reaction mixture, and the reaction is maintained at a constant temperature for 30 minutes. Following the addition of 10 µl stop buffer (formamide (20 ml), 1 M NaOH (200 µl), 0.5 M EDTA (400 µl), and 10 mg bromophenol blue), the reactions are separated on a preparative gel (12%) and visualized on a phosphorimager. Adenine sequencing (indicated by "A" at the top of the gel) is performed using double-stranded DNA Cycle Sequencing System from Life Technologies. The general sequence for the template strands is TCCAACTATGTATAC-INSERT-TTAGCGACACGCAATTGCTATAGTGAGTCGTATTA. Bands on the gel that exhibit slower mobility are indicative of quadruplex formation.

[0061] In another example of a polymerase arrest assay, a 5'- fluorescent-labeled (FAM) primer (P45, 15 nM) is mixed with template DNA (15nM) in a Tris-HCL buffer (15 mM Tris,

pH 7.5) containing 10mM MgCl₂, 0.1mM EDTA and 0.1mM mixed deoxynucleotide triphosphates (dNTP's). The FAM-P45 primer (5'- 6FAM-AGTCTGACTGTACGTAGCTAACAGACTCACTATAGCAATT-3') and the template DNA (5'-TCCAACATGTATACTGGGGA GGGTGGGGAGGGTGGGAAGGTT AGCGACACGCAATTGCTATAG TGAGTCGTATTAGCTACGTACAGTCAGTCAGACT-3') are synthesized and HPLC purified by Applied Biosystems. The mixture is denatured at 95°C for 5 minutes and, after cooling down to room temperature, is incubated at 37°C for 15 minutes. After cooling down to room temperature, 1mM KCl₂ and the test compound (various concentrations) are added and the mixture incubated for 15 minutes at room temperature. The primer extension is performed by adding 10mM KCl and Taq DNA Polymerase (2.5 U/reaction, Promega) and incubating at 70°C for 30 minutes. The reaction is stopped by adding 1 µl of the reaction mixture to 10 µl Hi-Di Formamide mixed and 0.25 µl LIZ120 size standard. Hi-Di Formamide and LIZ120 size standard are purchased from Applied Biosystems. The partially extended quadruplex arrest product is between 61 or 62 bases long and the full-length extended product is 99 bases long. The products are separated and analyzed using capillary electrophoresis. Capillary electrophoresis is performed using an ABI PRISM 3100-Avant Genetic Analyzer.

[0062] Certain arrest assays are performed in cells. In a transcription reporter assay, test quadruplex DNA is coupled to a reporter system, such that a formation or stabilization of a quadruplex structure can modulate a reporter signal. An example of such a system is a reporter expression system in which a polypeptide, such as luciferase or green fluorescent protein (GFP), is expressed by a gene operably linked to the potential quadruplex forming nucleic acid and expression of the polypeptide can be detected. As used herein, the term "operably linked" refers to a nucleotide sequence which is regulated by a sequence comprising the potential quadruplex forming nucleic acid. A sequence may be operably linked when it is on the same nucleic acid as the quadruplex DNA, or on a different nucleic acid. An exemplary luciferase reporter system is described herein. A luciferase promoter assay described in He, *et al.*, *Science* 281:1509-1512 (1998) often is utilized for the study of quadruplex formation. Specifically, a vector utilized for the assay is set forth in reference 11 of the He, *et al.*, document. In this assay, HeLa cells are transfected using the lipofectamin 2000-based system (Invitrogen) according to the manufacturer's protocol, using 0.1 µg of pRL-TK (Renilla luciferase reporter plasmid) and 0.9 µg of the quadruplex-forming plasmid. Firefly and Renilla luciferase activities are assayed

using the Dual Luciferase Reporter Assay System (Promega) in a 96-well plate format according to the manufacturer's protocol.

[0063] Circular dichroism (CD) sometimes is utilized to determine whether a candidate molecule interacts with a quadruplex nucleic acid. CD is particularly useful for determining whether a candidate molecule interacts with a nucleic acid *in vitro*. In certain embodiments, a candidate molecule is added to a DNA sample (5 µM each) in a buffer containing 10 mM potassium phosphate (pH 7.2) and 10 or 250 mM KCl at 37°C and then allowed to stand for 5 min at the same temperature before recording spectra. CD spectra are recorded on a Jasco J- 715 spectropolarimeter equipped with a thermoelectrically controlled single cell holder. CD intensity normally is detected between 220 nm and 320 nm and comparative spectra for DNA alone, candidate molecule alone, and the DNA with the candidate molecule are generated to determine the presence or absence of an interaction (*see e.g.* Datta *et al.*, *JACS* 123:9612-9619 (2001)). Spectra are arranged to represent the average of eight scans recorded at 100 nm/min. In certain embodiments, CD signals are monitored as a function of temperature. For example, CD signals indicative of the presence of a quadruplex structure in a sample can be determined and the loss or shift of those signals can be followed as a function of increasing temperature to determine at which temperature the quadruplex structure melts. The signals often are monitored in the presence of test molecule and in the absence of test molecule, and stabilizing molecules that increase the melting temperature of the quadruplex structure are identified as candidate molecules.

[0064] A cell proliferation assay is useful for assessing the utility of a candidate molecule for treating a cell proliferative disorder in a subject. In a cancer cell proliferation assay, cell proliferation rates are assessed as a function of different concentrations of test compounds added to the cell culture medium. Any cancer cell type can be utilized in the assay. In one embodiment, colon cancer cells are cultured *in vitro* and test compounds are added to the culture medium at varying concentrations. A useful colon cancer cell line is colo320, which is a colon adenocarcinoma cell line deposited with the National Institutes of Health as accession number JCRB0225. Parameters for using such cells are available at the http address cellbank.nihs.go.jp/cell/data/jcrb0225.htm.

Utilization of Candidate Molecules as Therapeutics

[0065] Because quadruplexes are regulators of biological processes such as oncogene transcription, modulators of quadruplex biological activity can be utilized as cancer therapeutics.

For example, molecules that stabilize quadruplex structures can exert a therapeutic effect for certain cell proliferative disorders and related conditions because quadruplex structures typically down-regulate the oncogene expression which can cause cell proliferative disorders.

Quadruplex-interacting candidate molecules can exert a biological effect according to different mechanisms, which include, for example, stabilizing a native quadruplex structure, inhibiting conversion of a native quadruplex to duplex DNA, and stabilizing a native quadruplex structure having a quadruplex-destabilizing nucleotide substitution. Thus, quadruplex interacting candidate molecules described herein may be administered to cells, tissues, or organisms, thereby down-regulating oncogene transcription and treating cell proliferative disorders. The terms "treating," "treatment" and "therapeutic effect" as used herein refer to reducing or stopping a cell proliferation rate (e.g., slowing or halting tumor growth) or reducing the number of proliferating cancer cells (e.g., removing part or all of a tumor) and refers to alleviating, completely or in part, a cell proliferation condition.

[0066] Quadruplex interacting molecules and quadruplex forming nucleic acids can be utilized to target a cell proliferative disorder. Cell proliferative disorders include, for example, colorectal cancers. Other examples of cancers include hematopoietic neoplastic disorders, which are diseases involving hyperplastic/neoplastic cells of hematopoietic origin (e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof). The diseases can arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acute megakaryoblastic leukemia. Additional myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, Crit. Rev. in *Oncol./Hematol.* 11:267-297 (1991)); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL), which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Sternberg disease. Cell proliferative disorders also include cancers of the colon, breast, lung, liver, pancreas, lymph node, colon, prostate, brain, head and neck, skin, liver, kidney, and heart. Candidate molecules also can be utilized to target cancer related processes and conditions, such as increased angiogenesis,

by inhibiting angiogenesis in a subject (e.g., molecules that stabilize a VEGF associated quadruplex structure can inhibit angiogenesis).

[0067] Thus, provided herein are methods for reducing cell proliferation or for treating or alleviating cell proliferative disorders, which comprise contacting a system having a nucleic acid comprising a native quadruplex with a candidate molecule identified herein. The system sometimes is a group of cells or one or more tissues, and often is a subject in need of a treatment of a cell proliferative disorder. A subject often is a mammal such as a mouse, rat, monkey, or human. One embodiment is a method for treating colorectal cancer by administering a candidate molecule that interacts with a *CMYC* regulatory nucleotide sequence to a subject in need thereof, thereby reducing the colorectal cancer cell proliferation. Another embodiment is a method for inhibiting angiogenesis and optionally treating a cancer associated with angiogenesis, which comprises administering a candidate molecule that interacts with a *VEGF* regulatory nucleotide sequence to a subject in need thereof, thereby reducing angiogenesis and optionally treating a cancer associated with angiogenesis. In another embodiment, a candidate molecule that interacts with a *HER2/neu* G-quadruplex is administered to a subject for the treatment of a fat cell proliferative disorder such as obesity.

[0068] Retroviruses offer a wealth of potential targets for G-quadruplex targeted therapeutics. G-quadruplex structures have been implicated as functional elements in at least two critical secondary structures formed by either viral RNA or DNA in HIV, the dimer linker structure (DLS) and the central DNA flap (CDF). Additionally, DNA aptamers which are able to adopt either inter- or intramolecular quadruplex structures are able to inhibit viral replication, by targeting either the envelope glycoprotein (putatively) or HIV-integrase respectively. Although not direct evidence, the latter observation indicates an involvement of native quadruplex structures in interaction with the integrase enzyme.

[0069] Dimer linker structures, which are common to all retroviruses, serve to bind two copies of the viral genome together by a non-covalent interaction between the two 5' ends of the two viral RNA sequences. The genomic dimer is stably associated with the gag protein in the mature virus particle. In the case of HIV, the origin of this non-covalent binding, may be traced to a 98 base-pair sequence containing several runs of at least two consecutive guanines, the 3'-most of which is critical for the formation of RNA dimers *in vitro*. An observed cation (potassium) dependence for the formation and stability of the dimer *in vitro*, in addition to the failure of an antisense sequence to effectively dimerize, has revealed the most likely binding structure to be an intermolecular G-quadruplex.

[0070] Prior to integration into the host genome, reverse transcribed viral DNA forms a pre-integration complex (PIC) with at least two major viral proteins, integrase and reverse transcriptase, which is subsequently transported into the nucleus by an as yet undefined mechanism. The Central DNA Flap (CDF) refers to 99-base length single-stranded tail of the + strand, occurring near the center of the viral duplex DNA, which is known to play a role in the nuclear import of the PIC. Oligonucleotide mimics of the CDF have been shown to form intermolecular G-quadruplex structures in cell-free systems.

[0071] Thus, candidate molecules can be used to stabilize the DLS and thus prevent decoupling of the two RNA strands, an event which is necessary for viral replication. Also, by binding to the quadruplex structure formed by the CDF, critical protein recognition and/or binding events necessary for nuclear transport of the PIC may be disrupted. In either case, a substantial advantage can exist over other anti-viral therapeutics. Current Highly Active Anti-Retroviral Therapeutic (HAART) regimes rely on the use of combinations of drugs targeted towards the HIV protease and HIV integrase. The requirement for multi-drug regimes is to minimize the emergence of resistance, which will usually develop rapidly when agents are used in isolation. The source of such rapid resistance is the infidelity of the reverse transcriptase enzyme which makes a mutation approx. once in every 10,000 base pairs. An advantage of targeting critical viral quadruplex structures over protein targets, is that the development of resistance is slow or is impossible. A point mutation of the target quadruplex, necessary to reduce affinity for the candidate molecule, can compromise the integrity of the critical quadruplex structure and lead to a non-functional copy of the virus. A single therapeutic agent based on this concept may replace the multiple drug regimes currently employed, with the concomitant benefits of reduced costs and the elimination of harmful drug/drug interactions.

[0072] Thus, provided herein are methods for inhibiting viral propagation in a system, which comprise contacting a system having a viral quadruplex-forming nucleic acid sequence with a candidate molecule described herein. The system sometimes is a group of cells or one or more tissues, and often is a subject in need of a treatment of a viral infection (e.g., a mammal such as a mouse, rat, monkey, or human). In an embodiment, provided is a method for treating HIV infection by administering a candidate molecule identified herein to a subject in need thereof, thereby reducing the HIV titers in the systems and alleviating infection.

[0073] Any suitable formulation of the candidate molecules described herein can be prepared for administration. Any suitable route of administration may be used, including but not limited to oral, parenteral, intravenous, intramuscular, topical and subcutaneous routes.

[0074] In cases where candidate molecules are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the candidate molecules as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α -ketoglutarate, and α -glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts are obtained using standard procedures well known in the art, for example by reacting a sufficiently basic candidate molecule such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids also are made.

[0075] In one embodiment, a candidate molecule is administered systemically (e.g., orally) in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active candidate molecule may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active candidate molecule. The percentage of the compositions and preparations may be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active candidate molecule in such therapeutically useful compositions is such that an effective dosage level will be obtained.

[0076] Tablets, troches, pills, capsules, and the like also may contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active candidate molecule, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as

cherry or orange flavor. Any material used in preparing any unit dosage form is pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active candidate molecule may be incorporated into sustained-release preparations and devices.

[0077] The active candidate molecule also may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active candidate molecule or its salts may be prepared in a buffered solution, often phosphate buffered saline, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The candidate molecule is sometimes prepared as a polymatrix-containing formulation for such administration (e.g., a liposome or microsome). Liposomes are described for example in U.S. Patent No. 5,703,055 (Felgner, *et al.*) and Gregoriadis, *Liposome Technology* vols. I to III (2nd ed. 1993).

[0078] The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient that are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0079] Sterile injectable solutions are prepared by incorporating the active candidate molecule in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum

drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

[0080] For topical administration, the present candidate molecules may be applied in liquid form. Candidate molecules often are administered as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid. Examples of useful dermatological compositions used to deliver candidate molecules to the skin are known (see, e.g., Jacquet, *et al.* (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith, *et al.* (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

[0081] Candidate molecules may be formulated with a solid carrier, which include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present candidate molecules can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

[0082] Generally, the concentration of the candidate molecule in a liquid composition often is from about 0.1 wt% to about 25 wt%, sometimes from about 0.5 wt% to about 10 wt%. The concentration in a semi-solid or solid composition such as a gel or a powder often is about 0.1 wt% to about 5 wt%, sometimes about 0.5 wt% to about 2.5 wt%. A candidate molecule composition may be prepared as a unit dosage form, which is prepared according to conventional techniques known in the pharmaceutical industry. In general terms, such techniques include bringing a candidate molecule into association with pharmaceutical carrier(s) and/or excipient(s) in liquid form or finely divided solid form, or both, and then shaping the product if required. The candidate molecule composition may be formulated into any dosage form, such as tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions also may be formulated as suspensions in aqueous, non-aqueous, or mixed media. Aqueous suspensions may further contain substances which increase viscosity, including for example, sodium carboxymethylcellulose, sorbitol, and/or dextran. The suspension may also contain one or more stabilizers.

[0083] The amount of the candidate molecule, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

[0084] A useful candidate molecule dosage often is determined by assessing its *in vitro* activity in a cell or tissue system and/or in vivo activity in an animal system. For example, methods for extrapolating an effective dosage in mice and other animals to humans are known to the art (see, e.g., U.S. Pat. No. 4,938,949). Such systems can be used for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population) of a candidate molecule. The dose ratio between a toxic and therapeutic effect is the therapeutic index and it can be expressed as the ratio ED₅₀/LD₅₀. The candidate molecule dosage often lies within a range of circulating concentrations for which the ED₅₀ is associated with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any candidate molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose sometimes is formulated to achieve a circulating plasma concentration range covering the IC₅₀ (i.e., the concentration of the test candidate molecule which achieves a half-maximal inhibition of symptoms) as determined in *in vitro* assays, as such information often is used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0085] Another example of effective dose determination for a subject is the ability to directly assay levels of "free" and "bound" candidate molecule in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" generated by molecular imprinting techniques. The candidate molecule is used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. Subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the candidate molecule and is able to selectively rebind the molecule under biological assay conditions (see, e.g., Ansell, *et al.*, *Current Opinion in Biotechnology* 7: 89-94 (1996) and in Shea, *Trends in Polymer Science* 2: 166-173 (1994)). Such "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix (see, e.g., Vlatakis, *et al.*, *Nature* 361: 645-647 (1993)). Through the use of isotope-labeling, "free" concentration of candidate molecule can be readily monitored and used in calculations of

IC_{50} . Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of candidate molecule. These changes can be readily assayed in real time using appropriate fiber optic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC_{50} . An example of such a "biosensor" is discussed in Kriz, *et al.*, *Analytical Chemistry* 67: 2142-2144 (1995).

[0086] Exemplary doses include milligram or microgram amounts of the candidate molecule per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific candidate molecule employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0087] Each document and publication cited is incorporated herein by reference in its entirety, including all figures, drawings, tables, text, and documents and publications referenced therein.

What is claimed is:

1. A method for identifying a candidate molecule that modulates a biological activity of a nucleic acid capable of forming a G-quadruplex structure, which comprises:
 - contacting a test molecule with the nucleic acid, wherein the nucleic acid or a portion thereof is in an intramolecular parallel G-quadruplex conformation; and
 - determining whether a portion of the test molecule interacts with a site located in the intramolecular parallel G-quadruplex conformation,whereby a test molecule having a portion that interacts with the site is identified as a candidate molecule that modulates the biological activity of the nucleic acid.
2. The method of claim 1, wherein the test molecule and the nucleic acid is contacted *in silico*.
3. The method of claim 1, wherein the nucleic acid is double-stranded.
4. The method of claim 1, wherein the nucleic acid is 30 or fewer nucleotides in length.
5. The method of claim 1, wherein the nucleic acid comprises a nucleotide sequence located 5' of the *CMYC* gene.
6. The method of claim 5, wherein the nucleic acid comprises the nucleotide sequence TG₄AG₃TG₄AG₃TG₄AAGG.
7. The method of claim 6, wherein the site comprises one or more atoms in a G-tetrad of the G-quadruplex.
8. The method of claim 1, which further comprises determining whether a portion of the test molecule interacts with a site in a secondary structure adjacent to the G-quadruplex.
9. The method of claim 8, wherein the secondary structure adjacent to the G-quadruplex is formed by a nucleotide sequence in a double stranded nucleic acid complementary to the nucleotide sequence that forms the G-quadruplex.

10. The method of claim 1 or 8, wherein a portion of the test molecule also intercalates with a duplex region adjacent to the G-quadruplex.
11. The method of claim 1, wherein the interaction is a hydrogen bond.
12. The method of claim 1, which further comprises determining whether a candidate molecule modulates a biological activity of the nucleic acid.
13. The method of claim 12, wherein the biological activity is an interaction of a protein with the nucleic acid.
14. The method of claim 13, wherein the protein is NM23-H2.
15. The method of claim 13, wherein the interaction is binding of the protein to the nucleic acid.
16. The method of claim 12, wherein the biological activity is DNA transcription.
17. The method of claim 12, wherein one or more nucleotides of the nucleic acid is substituted with a fluorescent nucleotide analog and the biological activity is determined by detecting the fluorescence of the nucleic acid.
18. A method for identifying a therapeutic that reduces cell proliferation in a system, which comprises contacting a system with a candidate molecule identified by the method of claim 1 and determining whether the candidate molecule reduces cell proliferation in the system, whereby a candidate molecule that reduces cell proliferation in the system is identified as the therapeutic.
19. The method of claim 18 wherein the system is a group of cells.
20. The method of claim 18 wherein the system is an animal.
21. A method for stabilizing an intramolecular parallel G-quadruplex conformation of a nucleic acid, which comprises contacting the nucleic acid with a quadruplex-interacting

molecule in the system, whereby the molecule stabilizes the intramolecular parallel G-quadruplex conformation.

22. The method of claim 21, wherein the system is a group of cells.
23. The method of claim 21, wherein the system is an animal.
24. A method for treating a cell proliferative condition in a subject, which comprises administering a candidate compound identified by the method of claim 1 or a therapeutic identified by the method of claim 18 to a subject in need thereof, whereby administering the candidate compound or the therapeutic reduces cell proliferation in the subject.
25. The method of claim 24, wherein the cell proliferative condition is a cancer.
26. The method of claim 25, wherein the cell proliferative condition is colorectal cancer.
27. The method of claim 24, wherein the cell proliferative condition is angiogenesis.

Abstract of the Disclosure

Featured herein is a method for identifying candidate molecules that interact with a nucleic acid having an intramolecular parallel quadruplex structure. The candidate molecules often are screened *in vitro* to determine whether they modulate the biological activity of the nucleic acid and sometimes are administered to a subject *in vivo* to treat a cell proliferative condition. Also provided are methods for stabilizing an intramolecular parallel G-quadruplex conformation of a nucleic acid by contacting the nucleic acid with a quadruplex-interacting molecule.

FIGURE 1




FIGURE 2





FIGURE 3



Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	METHODS FOR IDENTIFYING MODULATORS OF QUADRUPLEX NUCLEIC ACIDS
Attorney Docket Number::	532233001400
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets::	3
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United Kingdom
Status::	Full Capacity
Given Name::	Adam
Family Name::	SIDDIQUI-JAIN
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	2334 Hillery Drive, #13206
City of mailing address::	San Diego
State or Province of mailing address::	CA

Postal or Zip Code of mailing address:: 92126

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Laurence
Middle Name:: H.
Family Name:: HURLEY
City of Residence:: Tucson
State or Province of Residence:: AZ
Country of Residence:: US
Street of mailing address:: 5000 E. Gleneagles Drive
City of mailing address:: Tucson
State or Province of mailing address:: AZ
Postal or Zip Code of mailing address:: 85718

Correspondence Information

Correspondence Customer Number:: 25225

Representative Information

Representative Customer Number:: 25225

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/037789

International filing date: 12 November 2004 (12.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/520,908
Filing date: 17 November 2003 (17.11.2003)

Date of receipt at the International Bureau: 17 December 2004 (17.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.